Clinical Trials Browser

Phase 3 × Breast Neoplasms × disitamab vedotin × Clear all

NCT05904964 2023-06-22

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Phase 3 Recruiting

Breast Neoplasms